1
/
of
1
Human Tumor Necrosis Factor Ligand Superfamily Member 11 (TNFSF11) ELISA Kit
Human Tumor Necrosis Factor Ligand Superfamily Member 11 (TNFSF11) ELISA Kit
This ELISA kit is designed to detect Human Tumor Necrosis Factor Ligand Superfamily Member 11 (Human TNFSF11). The assay plate has been pre-coated with mouse anti-Human RANKL monoclonal antibody. When the sample containing RANKL is added to the plate, it binds to the antibodies coated on the wells. Then, a horseradish peroxidase conjugated mouse anti-Human RANKL Antibody is added to the wells and binds to RANKL in the sample. After washing the wells, substrate solutions are added, and the color intensity is directly proportional to the amount of Human RANKL present. The reaction is stopped by adding an acidic stop solution, and the absorbance is measured at 450 nm.
Catalog No:
BPE215
Regular price
$624.00 USD
Regular price
$480.00 USD
Sale price
$624.00 USD
Unit price
/
per
2 weeks
Couldn't load pickup availability
Product Details
Species Reactivity
Human
Sensitivity
56.61 pg/mL
Detection Range
234.38-15000 pg/mL
Sample Type
Serum, plasma, cell culture supernates
Incubation(s)
3.5 hour(s)
Research Areas
Cancer, Cardiovascular, Immunology
Background
Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein that belongs to the tumor necrosis factor family. The receptor activator of nuclear factor-kappaB ligand (RANKL), its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption. RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation. Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy. Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested. Inhibition of RANKL function via the natural decoy receptor osteoprotegerin (OPG, TNFRSF11B) prevents bone loss in postmenopausal osteoporosis and cancer metastases. Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis. RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease. In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Cancer Immunotherapy Immune Checkpoint Immunotherapy Targeted Therapy
Shipping Condition
Shipped on cold gel packs.
Storage Condition and Shelf Life
This product can be stored at 2-8C.
Analyte
Tumor necrosis factor ligand superfamily member 11
Regulatory Status
For Research Use Only
